Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.83+0.30 (+1.05%)
Close on Nov 13, 2026Market cap $2.26BP/E –Yield –
Celldex Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Celldex Therapeutics's total assets was $721.53M at Sep 30, 2026. For fiscal 2025 it was $582.98M, down 26.4% from the year before. Over ten years it grew 5.6% a year on average. The highest annual figure on record is $792.34M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $582.98M | -26.4% |
| FY2024 | Dec 31, 2024 | $792.34M | +70.2% |
| FY2023 | Dec 31, 2023 | $465.63M | +32.0% |
| FY2022 | Dec 31, 2022 | $352.74M | -20.7% |
| FY2021 | Dec 31, 2021 | $444.65M | +88.5% |
| FY2020 | Dec 31, 2020 | $235.84M | +91.8% |
| FY2019 | Dec 31, 2019 | $122.93M | -21.1% |
| FY2018 | Dec 31, 2018 | $155.81M | -50.6% |
| FY2017 | Dec 31, 2017 | $315.62M | -17.7% |
| FY2016 | Dec 31, 2016 | $383.36M | +13.6% |
| FY2015 | Dec 31, 2015 | $337.58M | +36.1% |
| FY2014 | Dec 31, 2014 | $248.01M | -28.5% |
| FY2013 | Dec 31, 2013 | $347.10M | +176.5% |
| FY2012 | Dec 31, 2012 | $125.54M | +28.1% |
| FY2011 | Dec 31, 2011 | $97.99M | -10.9% |
| FY2010 | Dec 31, 2010 | $109.94M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $721.53M | +11.3% |
| Q2 FY2026 | Jun 30, 2026 | $782.35M | +13.0% |
| Q1 FY2026 | Mar 31, 2026 | $511.25M | -30.9% |
| Q4 FY2025 | Dec 31, 2025 | $582.98M | -26.4% |
| Q3 FY2025 | Sep 30, 2025 | $648.44M | -21.2% |
| Q2 FY2025 | Jun 30, 2025 | $692.41M | -18.1% |
| Q1 FY2025 | Mar 31, 2025 | $739.47M | -14.9% |
| Q4 FY2024 | Dec 31, 2024 | $792.34M | +70.2% |
| Q3 FY2024 | Sep 30, 2024 | $823.18M | +193.7% |
| Q2 FY2024 | Jun 30, 2024 | $845.59M | +182.5% |
| Q1 FY2024 | Mar 31, 2024 | $868.85M | +167.7% |
| Q4 FY2023 | Dec 31, 2023 | $465.63M | +32.0% |
| Q3 FY2023 | Sep 30, 2023 | $280.26M | -24.1% |
| Q2 FY2023 | Jun 30, 2023 | $299.31M | -25.7% |
| Q1 FY2023 | Mar 31, 2023 | $324.52M | -23.5% |
| Q4 FY2022 | Dec 31, 2022 | $352.74M | -20.7% |
| Q3 FY2022 | Sep 30, 2022 | $369.23M | -19.8% |
| Q2 FY2022 | Jun 30, 2022 | $402.96M | +97.0% |
| Q1 FY2022 | Mar 31, 2022 | $424.04M | +93.6% |
| Q4 FY2021 | Dec 31, 2021 | $444.65M | +88.5% |
| Q3 FY2021 | Sep 30, 2021 | $460.20M | +79.9% |
| Q2 FY2021 | Jun 30, 2021 | $204.55M | -21.7% |
| Q1 FY2021 | Mar 31, 2021 | $219.07M | +94.7% |
| Q4 FY2020 | Dec 31, 2020 | $235.84M | +91.8% |
| Q3 FY2020 | Sep 30, 2020 | $255.77M | +94.0% |
| Q2 FY2020 | Jun 30, 2020 | $261.40M | +83.8% |
| Q1 FY2020 | Mar 31, 2020 | $112.50M | -23.8% |
| Q4 FY2019 | Dec 31, 2019 | $122.93M | -21.1% |
| Q3 FY2019 | Sep 30, 2019 | $131.84M | -21.7% |
| Q2 FY2019 | Jun 30, 2019 | $142.24M | -20.3% |
| Q1 FY2019 | Mar 31, 2019 | $147.58M | -22.9% |
| Q4 FY2018 | Dec 31, 2018 | $155.81M | -50.6% |
| Q3 FY2018 | Sep 30, 2018 | $168.29M | -47.3% |
| Q2 FY2018 | Jun 30, 2018 | $178.38M | -48.5% |
| Q1 FY2018 | Mar 31, 2018 | $191.38M | -46.8% |
| Q4 FY2017 | Dec 31, 2017 | $315.62M | -17.7% |
| Q3 FY2017 | Sep 30, 2017 | $319.42M | – |
| Q2 FY2017 | Jun 30, 2017 | $346.07M | – |
| Q1 FY2017 | Mar 31, 2017 | $360.05M | – |
| Q4 FY2016 | Dec 31, 2016 | $383.36M | – |
See a number that looks wrong?